Lataa...
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternat...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685399/ https://ncbi.nlm.nih.gov/pubmed/23807861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S45193 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|